Found: 4
Select item for more details and to access through your institution.
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02551
- By:
- Publication type:
- Article
Elotuzumab Promotes Self-Engagement of Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7) Between Natural Killer (NK) and Multiple Myeloma (MM) Cells to Enhance Cytotoxicity.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S253, doi. 10.1016/j.clml.2018.07.156
- By:
- Publication type:
- Article
Regulation of the Functions of Natural Cytotoxicity Receptors by interactions with Diverse Ligands and Alterations in Splice variant expression.
- Published in:
- Frontiers in Immunology, 2017, v. 8, p. 1, doi. 10.3389/fimmu.2017.00369
- By:
- Publication type:
- Article
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 2, p. 226, doi. 10.3390/cancers13020226
- By:
- Publication type:
- Article